Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load

Journal of Clinical Oncology

Volumn 28, Issue 21, 2010, Pages

  Oude Munnink, Thijs H ^a   Dijkers, Eli C ^a   Netters, Sabine J ^a   Lub de Hooge, Marjolijn N ^a   Brouwers, Adrienne H ^a   Haasjes, Janny G ^b   Schröder, Carolina P ^a   De Vries, Elisabeth G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Bethesda Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB; UNCLASSIFIED DRUG; ZIRCONIUM 89; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; RADIOISOTOPE; ZIRCONIUM;

BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; LETTER; LIVER METASTASIS; LOADING DRUG DOSE; METASTASIS; PLASMA CONCENTRATION-TIME CURVE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STEADY STATE; BREAST TUMOR; CHEMISTRY; NOTE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; RADIOISOTOPES; RECEPTOR, ERBB-2; ZIRCONIUM;

EID: 77955283683     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.4604     Document Type: Letter

References (7)

1. Leyland-Jones B, Colomer R, Trudeau ME, et al: Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. J Clin Oncol 28:960-966, 2010
2. FDA clinical review of BLA 98-0369: Herceptin trastuzumab (rhuMAb HER2). http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm091373.pdf
3. Bruno R, Washington CB, Lu JF, et al: Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56:361-369, 2005 (Pubitemid 41095399)
4. Perik PJ, Lub-de Hooge MN, Gietema JA, et al: Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24:2276-2282, 2006 (Pubitemid 46630657)
5. 89Zr- trastuzumab biodistribution and HER2 PET imaging in metastatic breast cancer patients. Clin Pharmacol Ther doi: 10.1038/clpt.2010.12 (epub ahead of print on March 31, 2010)
6. Pegram MD, Konecny G, Slamon DJ: The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 103:57-75, 2000
7. Yoshizumi T, Gondolesi GE, Bodian CA, et al: A simple new formula to assess liver weight. Transplant Proc 35:1415-1420, 2003 (Pubitemid 36765547)